New hope for when standard breast cancer drugs stop working
NCT ID NCT04090567
Summary
This study is testing two new drug combinations for people with advanced, BRCA-positive breast cancer that has spread and has stopped responding to a standard type of targeted therapy (PARP inhibitors). The trial will see if adding a second drug to the standard one can shrink tumors and control the cancer again. It is for adults with this specific type of breast cancer who have already tried and progressed on a PARP inhibitor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE III BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.